A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities

被引：10
作者：
Liao, Xuemei [1 ]
Ye, Hui [2 ]
Si, Tianmei [1 ]
机构：
[1] Peking Univ, Peking Univ Sixth Hosp, Natl Clin Res Ctr Mental Disorders, NHC Key Lab Mental Hlth,Inst Mental Hlth, Huayuanbeilu 51, Beijing 100191, Peoples R China
[2] Sanofi, Dept Med, Shanghai, Peoples R China
来源：
NEUROPSYCHIATRIC DISEASE AND TREATMENT | 2021年 / 17卷
基金：
国家重点研发计划;
关键词：
antipsychotics; switch; metabolic syndrome; INDUCED WEIGHT-GAIN; DOUBLE-BLIND; LONG-TERM; ATYPICAL ANTIPSYCHOTICS; BIPOLAR DISORDER; DRUG TREATMENT; ARIPIPRAZOLE; OLANZAPINE; RISK; PREVALENCE;
D O I：
10.2147/NDT.S294521
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Metabolic syndrome (MetS) in patients with schizophrenia occurs 2-3 times more frequently than in the general population. Antipsychotic medication is a primary risk factor for patients with MetS. In particular, the widely used second-generation antipsychotics can affect glucose and lipid metabolism and can induce insulin resistance and other metabolic abnormalities through various receptors. Notably, the metabolic risks of various anti psychotics may differ because of their different pharmacological affinity to MetS-related receptors. Several previous studies have shown that switching from high to low metabolic risk antipsychotics may improve patients' metabolic parameters. The current review aims to discuss the strategies for switching antipsychotic medications and the impact on metabolic abnormalities in patients with schizophrenia.
引用
收藏
页码：453 / 469
页数：17
相关论文
共 50 条
  • [31] Metabolic syndrome in antipsychotic naive patients diagnosed with schizophrenia
    Grover, Sandeep
    Nebhinani, Naresh
    Chakrabarti, Subho
    Parakh, Preeti
    Ghormode, Deepak
    EARLY INTERVENTION IN PSYCHIATRY, 2012, 6 (03) : 326 - 331
  • [32] Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
    Boiko, Anastasiia S.
    Mednova, Irina A.
    Kornetova, Elena G.
    Bokhan, Nikolay A.
    Semke, Arkadiy, V
    Loonen, Anton J. M.
    Ivanova, Svetlana A.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 1051 - 1058
  • [33] Lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophrenia
    Tocco, Michael
    Newcomer, John W.
    Mao, Yongcai
    Pikalov, Andrei
    Loebel, Antony
    CNS SPECTRUMS, 2021, 26 (06) : 614 - 624
  • [34] Prevalence of metabolic syndrome among patients with schizophrenia in Japan
    Sugawara, Norio
    Yasui-Furukori, Norio
    Sato, Yasushi
    Umeda, Takashi
    Kishida, Ikuko
    Yamashita, Hakuei
    Saito, Manabu
    Furukori, Hanako
    Nakagami, Taku
    Hatakeyama, Mitsunori
    Nakaji, Shigeyuki
    Kaneko, Sunao
    SCHIZOPHRENIA RESEARCH, 2010, 123 (2-3) : 244 - 250
  • [35] Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study
    Lee, Jung Sun
    Kwon, Jun Soo
    Kim, Daeho
    Kim, Sung-Wan
    Kim, Jae-Jin
    Kim, Jong-Noon
    Nam, Hee Jung
    Ryu, Seunghyong
    Park, Il Ho
    An, Suk Kyoon
    Oh, Hong-Seok
    Won, Seunghee
    Lee, Kanguk
    Lee, Young
    Lee, Seung-Hwan
    Lee, Yu Sang
    Yi, Jung-Seo
    Hong, Kyung Sue
    Joo, Yeon Ho
    PSYCHIATRY INVESTIGATION, 2017, 14 (01) : 44 - 50
  • [36] Relationship between metabolic syndrome and cognition in patients with schizophrenia
    Lindenmayer, Jean Pierre
    Khan, Anzalee
    Kaushik, Saurabh
    Thanju, Amod
    Praveen, Rajalakshmi
    Hoffman, Lisa
    Cherath, Lata
    Valdez, Gladys
    Wance, Deborah
    SCHIZOPHRENIA RESEARCH, 2012, 142 (1-3) : 171 - 176
  • [37] Relationship of metabolic syndrome and neurocognitive deficits in patients with schizophrenia
    Grover, Sandeep
    Padmavati, R.
    Sahoo, Swapnajeet
    Gopal, Subhashini
    Nehra, Ritu
    Ganesh, Arthi
    Raghavan, Vijaya
    Sankaranarayan, Anoop
    PSYCHIATRY RESEARCH, 2019, 278 : 56 - 64
  • [38] Metabolic Syndrome Associated with Schizophrenia and Atypical Antipsychotics
    Hasnain, Mehrul
    Fredrickson, Sonja K.
    Vieweg, W. Victor R.
    Pandurangi, Anand K.
    CURRENT DIABETES REPORTS, 2010, 10 (03) : 209 - 216
  • [39] Prevalence of metabolic syndrome in Iranian patients with schizophrenia: A systematic review and meta-analysis
    Shojaeimotlagh, Vahid
    Hashiehbaf, Atieh
    Karami, Maryam
    Monjazebi, Fateme
    Gheshlagh, Reza Ghanei
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2019, 13 (01) : 143 - 147
  • [40] The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review
    Papanastasiou, Evangelos
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2013, 3 (01) : 33 - 51
12345